Reviews in Endocrine and Metabolic Disorders

, Volume 18, Issue 4, pp 393–410 | Cite as

Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?

  • Christian Fottner
  • Martina Ferrata
  • Matthias M. Weber
Article

Abstract

Neuroendocrine neoplasms of the digestive system (GEP-NEN) represent a heterogeneous group of malignancies with various clinical presentation and prognosis. GEP-NENs can potentially affect all organs of the gastrointestinal tract; characteristically they share the biological property to produce and secrete peptides and neuroamines. About 30% of GEP-NENs are hormonally active and can cause specific clinical syndromes. The clinical presentation mainly depends on the primary site of the tumor and its functionality. Because of the wide spectrum of clinical symptoms and their misperceived rarity, diagnosis of GEP-NENs is often delayed for years and tumors are detected first in an advanced stage. Early identification of a specific hormonal syndrome can significantly impact tumor diagnosis and treatment, moreover the preoperative management of NEN hormonal release avoids potential life threatening hormonal crisis. However, GEP-NEN diagnostic work-up is challenging, it requires a multidisciplinary team and needs particular experience; standardized protocols and clinical experience are essential for a proper endocrine diagnostic work-up. In addition to the biochemical diagnostic, further radiologic and endoscopic imaging modalities are required moreover, somatostatin-receptor based functional imaging, using either Octreotide-scintigraphy or novel PET-based techniques with specific isotopes like Ga68-DOTA-octreotate, plays an important role for the detection of the primary tumor as well as for the evaluation of the tumor extent.

Keywords

Neuroendocrine neoplasm Gastroenteropancreatic GEP NEN Hormonally active Functional Syndrome Carcinoid Gastrinoma Zollinger ellison Insulinoma Whipple´s triad VIP Ectopic ACTH 

Notes

Compliance with ethical standards

Conflict of interest

CF and MMW received financial sponsorship for congress attendences and lectures from Novartis, Ipsen and Pfizer. MMW received unrestricted research grants by Novartis and Ipsen.

References

  1. 1.
    Ahlman H, Nilsson. The gut as the largest endocrine organ in the body. Ann Oncol. 2001;12(Suppl 2):S63–8.  https://doi.org/10.1093/annonc/12.suppl_2.S63.CrossRefPubMedGoogle Scholar
  2. 2.
    Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.  https://doi.org/10.1200/JCO.2007.15.4377.CrossRefPubMedGoogle Scholar
  3. 3.
    Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer. 2001;94(3):444–8.  https://doi.org/10.1002/ijc.1473.CrossRefPubMedGoogle Scholar
  4. 4.
    Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer. 2000;83(7):952–5.  https://doi.org/10.1054/bjoc.2000.1394.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.  https://doi.org/10.1016/S1470-2045(07)70410-2.CrossRefPubMedGoogle Scholar
  6. 6.
    Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.  https://doi.org/10.1002/cncr.11105.CrossRefPubMedGoogle Scholar
  7. 7.
    Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8(1):54–64.  https://doi.org/10.1038/nrendo.2011.120.CrossRefPubMedGoogle Scholar
  8. 8.
    Lam JC, Xu A, Tam S, et al. Hypoadiponectinemia is related to sympathetic activation and severity of obstructive sleep apnea. Sleep. 2008;31(12):1721–7.  https://doi.org/10.1093/sleep/31.12.1721.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bosman FTCF, Hruban RH, Theise ND. World Health Organization (WHO) classification of Tumours of the digestive system. 4th ed. Geneva: WHO Press; 2010.Google Scholar
  10. 10.
    Tang LH, Basturk O, Sue JJ, Klimstra DSA. Practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–202.  https://doi.org/10.1097/PAS.0000000000000662.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Karges W, Adler G. Clinical genetics of neuroendocrine tumors. Med Klin (Munich). 2003;98(12):712–6.  https://doi.org/10.1007/s00063-003-1317-2.CrossRefGoogle Scholar
  12. 12.
    Anlauf M, Garbrecht N, Bauersfeld J, et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 2007;451(Suppl 1):S29–38.CrossRefPubMedGoogle Scholar
  13. 13.
    Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.  https://doi.org/10.1210/jc.2012-1230.CrossRefPubMedGoogle Scholar
  14. 14.
    Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15(2):409–27.  https://doi.org/10.1677/ERC-07-0221.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34(3):300–13.  https://doi.org/10.1097/PAS.0b013e3181ce1447.CrossRefPubMedGoogle Scholar
  16. 16.
    Hofer MD, Chang MC, Hirko KA, Rubin MA, Nose V. Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Mod Pathol. 2009;22(7):933–9.  https://doi.org/10.1038/modpathol.2009.50.CrossRefPubMedGoogle Scholar
  17. 17.
    Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbeck's Arch Surg. 2011;396(8):1145–56.  https://doi.org/10.1007/s00423-011-0794-7.CrossRefGoogle Scholar
  18. 18.
    Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19(5):753–81.  https://doi.org/10.1016/j.bpg.2005.06.002.CrossRefPubMedGoogle Scholar
  19. 19.
    Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32.  https://doi.org/10.1136/gutjnl-2011-300831.CrossRefPubMedGoogle Scholar
  20. 20.
    Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–38.  https://doi.org/10.1159/000443170.CrossRefPubMedGoogle Scholar
  21. 21.
    Srirajaskanthan R, Ahmed A, Prachialias A, Srinivasan P, Heaton N, Jervis N, et al. ENETS TNM staging predicts prognosis in small bowel neuroendocrine Tumours. ISRN Oncol. 2013;2013:420795.  https://doi.org/10.1155/2013/420795.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EA. Single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas. 2013;42(3):405–10.  https://doi.org/10.1097/MPA.0b013e318271c0d5.CrossRefPubMedGoogle Scholar
  23. 23.
    Adaway JE, Dobson R, Walsh J, Cuthbertson DJ, Monaghan PJ, Trainer PJ, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2016;53(Pt 5):554–60.  https://doi.org/10.1177/0004563215613109.CrossRefPubMedGoogle Scholar
  24. 24.
    Gregg Mamikunian AIV, O’Dorisio TM, Woltering EA, Go VLW. Neuroendocrine tumora a comprehensive guide to diagnosis and management fourth edition. Inter Science Institute; 2009.Google Scholar
  25. 25.
    Hannah-Shmouni F, Stratakis CA, Koch CA. Flushing in (neuro)endocrinology. Rev Endocr Metab Disord. 2016;17(3):373–80.  https://doi.org/10.1007/s11154-016-9394-8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19(6):829–37.  https://doi.org/10.3748/wjg.v19.i6.829.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Marks V. Recognition and differential diagnosis of spontaneous hypoglycaemia. Clin Endocrinol. 1992;37(4):309–16.  https://doi.org/10.1111/j.1365-2265.1992.tb02329.x.CrossRefGoogle Scholar
  28. 28.
    Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the Management of Patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.  https://doi.org/10.1159/000443171.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(3):709–28.  https://doi.org/10.1210/jc.2008-1410.CrossRefPubMedGoogle Scholar
  30. 30.
    Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-Peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007;157(1):75–83.  https://doi.org/10.1530/EJE-07-0109.CrossRefPubMedGoogle Scholar
  31. 31.
    Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711–9.  https://doi.org/10.1016/S0025-6196(12)62083-7.CrossRefPubMedGoogle Scholar
  32. 32.
    Anlauf M, Bauersfeld J, Raffel A, Koch CA, Henopp T, Alkatout I, et al. Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. Am J Surg Pathol. 2009;33(3):339–46.  https://doi.org/10.1097/PAS.0b013e3181874eca.CrossRefPubMedGoogle Scholar
  33. 33.
    Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106(3):307–10.  https://doi.org/10.1016/S0002-9343(99)00021-2.CrossRefPubMedGoogle Scholar
  34. 34.
    Guettier JM, Lungu A, Goodling A, Cochran C, Gorden P. The role of proinsulin and insulin in the diagnosis of insulinoma: a critical evaluation of the Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4752–8.  https://doi.org/10.1210/jc.2013-2182.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Service FJ, Natt N. The prolonged fast. J Clin Endocrinol Metab. 2000;85(11):3973–4.  https://doi.org/10.1210/jcem.85.11.6934.CrossRefPubMedGoogle Scholar
  36. 36.
    Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, et al. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers. 2011;26(2):94–101.  https://doi.org/10.5301/JBM.2011.8327.CrossRefPubMedGoogle Scholar
  37. 37.
    Hirshberg B, Skarulis MC, Pucino F, Csako G, Brennan R, Gorden P. Repaglinide-induced factitious hypoglycemia. J Clin Endocrinol Metab. 2001;86(2):475–7.  https://doi.org/10.1210/jcem.86.2.7160.CrossRefPubMedGoogle Scholar
  38. 38.
    Freckmann G, Schmid C, Baumstark A, Pleus S, Link M, Haug C. System accuracy evaluation of 43 blood glucose monitoring systems for self-monitoring of blood glucose according to DIN EN ISO 15197. J Diabetes Sci Technol. 2012;6(5):1060–75.  https://doi.org/10.1177/193229681200600510.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Eisenberg D, Azagury DE, Ghiassi S, Grover BT, Kim JJASMBS. Position statement on postprandial Hyperinsulinemic hypoglycemia after bariatric surgery. Surg Obes Relat Dis. 2017;13(3):371–8.  https://doi.org/10.1016/j.soard.2016.12.005.CrossRefPubMedGoogle Scholar
  40. 40.
    Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000;79(6):379–411.  https://doi.org/10.1097/00005792-200011000-00004.CrossRefGoogle Scholar
  41. 41.
    Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401.  https://doi.org/10.1007/s00428-006-0250-1.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98–119.  https://doi.org/10.1159/000335591.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Wilson SD, Doffek KM, Krzywda EA, Quebbeman EJ, Christians KK, Pappas SG. Zollinger-Ellison syndrome associated with a history of alcohol abuse: coincidence or consequence? Surgery. 2011;150(6):1129–35.  https://doi.org/10.1016/j.surg.2011.09.004.CrossRefPubMedGoogle Scholar
  44. 44.
    Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012;10(2):199–202.  https://doi.org/10.1016/j.cgh.2011.08.012.CrossRefPubMedGoogle Scholar
  45. 45.
    Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006;85(6):331–64.  https://doi.org/10.1097/MD.0b013e31802b518c.CrossRefGoogle Scholar
  46. 46.
    McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology. 1980;79(6):1324–31.PubMedGoogle Scholar
  47. 47.
    O'Toole D, Grossman A, Gross D, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90(2):194–202.  https://doi.org/10.1159/000225948.CrossRefPubMedGoogle Scholar
  48. 48.
    Hubbard H, Goodgame R. Evaluation of possible gastrinoma. MedGenMed. 2007;9(1):31.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85(6):295–330.  https://doi.org/10.1097/01.md.0000236956.74128.76.CrossRefGoogle Scholar
  50. 50.
    Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J Gastroenterol. 2012;18(39):5495–503.  https://doi.org/10.3748/wjg.v18.i39.5495.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Sanchez W. Mayo clinic gastroenterology and hepatology board review. Oxford University Press, Incorporate; 2014 28 ago, p. 57–72.Google Scholar
  52. 52.
    Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res. 2004;120(1):139–61.  https://doi.org/10.1016/j.jss.2003.12.007.CrossRefPubMedGoogle Scholar
  53. 53.
    Singer J, Werner F, Koch CA, et al. Ectopic Cushing's syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum. Exp Clin Endocrinol Diabetes. 2010;118(8):524–9.  https://doi.org/10.1055/s-0029-1243634.CrossRefPubMedGoogle Scholar
  54. 54.
    Pape UF, Maasberg S, Jann H, Pschowski R, Krüger S, Prasad V, et al. Management of follow-up of neuroendocrine neoplasias. Best Pract Res Clin Endocrinol Metab. 2016;30(1):129–40.  https://doi.org/10.1016/j.beem.2016.02.001.CrossRefPubMedGoogle Scholar
  55. 55.
    Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013;31(13):1690–8.  https://doi.org/10.1200/JCO.2012.47.1912.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25(15):1967–73.  https://doi.org/10.1200/JCO.2006.10.1535.CrossRefPubMedGoogle Scholar
  57. 57.
    Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, et al. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology. 2012;95(4):344–50.  https://doi.org/10.1159/000333853.CrossRefPubMedGoogle Scholar
  58. 58.
    Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol. 2004;60(5):644–52.  https://doi.org/10.1111/j.1365-2265.2004.02030.x.CrossRefGoogle Scholar
  59. 59.
    Tomassetti P, Migliori M, Simoni P, Casadei R, de Iasio R, Corinaldesi R, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2001;13(1):55–8.  https://doi.org/10.1097/00042737-200101000-00010.CrossRefPubMedGoogle Scholar
  60. 60.
    Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol. 2008;20(1):1–12.  https://doi.org/10.1097/CCO.0b013e3282f1c595.CrossRefPubMedGoogle Scholar
  61. 61.
    Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17(9):2427–43.  https://doi.org/10.1245/s10434-010-1006-3.CrossRefPubMedGoogle Scholar
  62. 62.
    Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):111–134, viii.  https://doi.org/10.1016/j.ecl.2010.12.001.CrossRefGoogle Scholar
  63. 63.
    Stridsberg M, Eriksson B, Oberg K, Janson ETA. Comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177(2):337–41.  https://doi.org/10.1677/joe.0.1770337.CrossRefPubMedGoogle Scholar
  64. 64.
    Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717–51.  https://doi.org/10.1053/j.gastro.2005.03.038.CrossRefPubMedGoogle Scholar
  65. 65.
    Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, et al. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord. 2014;14(1):64.  https://doi.org/10.1186/1472-6823-14-64.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Gut P, Czarnywojtek A, Fischbach J, Bączyk M, Ziemnicka K, Wrotkowska E, et al. Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci. 2016;12(1):1–9.  https://doi.org/10.5114/aoms.2016.57577.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Ardill JE, O'Dorisio TM. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin N Am. 2010;39(4):777–90.  https://doi.org/10.1016/j.ecl.2010.09.001.CrossRefGoogle Scholar
  68. 68.
    Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O'Toole D, Pascher A, Reed N, Sundin A, Vullierme MP. Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017;105(3):310–19.  https://doi.org/10.1159/000458155.
  69. 69.
    Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali A, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Investig. 2004;27(1):6–11.  https://doi.org/10.1007/BF03350903.CrossRefGoogle Scholar
  70. 70.
    Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin AG, Chayvialle JA, et al. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer. 2012;48(12):1766–73.  https://doi.org/10.1016/j.ejca.2011.11.005.CrossRefPubMedGoogle Scholar
  71. 71.
    Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95(9):2271–7.  https://doi.org/10.1111/j.1572-0241.2000.02480.x.CrossRefPubMedGoogle Scholar
  72. 72.
    Hoeffel C, Job L, Ladam-Marcus V, Vitry F, Cadiot G, Marcus C. Detection of hepatic metastases from carcinoid tumor: prospective evaluation of contrast-enhanced ultrasonography. Dig Dis Sci. 2009;54(9):2040–6.  https://doi.org/10.1007/s10620-008-0570-x.CrossRefPubMedGoogle Scholar
  73. 73.
    Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(Suppl 4):iv1–16.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003;181(4):987–92.  https://doi.org/10.2214/ajr.181.4.1810987.CrossRefPubMedGoogle Scholar
  75. 75.
    Bailey AA, Debinski HS, Appleyard MN, Remedios ML, Hooper JE, Walsh AJ, et al. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol. 2006;101(10):2237–43.  https://doi.org/10.1111/j.1572-0241.2006.00749.x.CrossRefPubMedGoogle Scholar
  76. 76.
    Bellutti M, Fry LC, Schmitt J, Seemann M, Klose S, Malfertheiner P, et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci. 2009;54(5):1050–8.  https://doi.org/10.1007/s10620-008-0456-y.CrossRefPubMedGoogle Scholar
  77. 77.
    Miederer M, Weber MM, Fottner C. Molecular imaging of gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin N Am. 2010;39(4):923–35.  https://doi.org/10.1016/j.gtc.2010.08.031.CrossRefGoogle Scholar
  78. 78.
    Guettier JM, Kam A, Chang R, Skarulis MC, Cochran C, Alexander HR, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab. 2009;94(4):1074–80.  https://doi.org/10.1210/jc.2008-1986.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Christian Fottner
    • 1
  • Martina Ferrata
    • 1
    • 2
  • Matthias M. Weber
    • 1
  1. 1.Schwerpunkt Endokrinologie und Stoffwechselerkrankungen, I. Medizinischen Klinik und Poliklinik; ENETS center of excellenceUniversitätsmedizin der Johannes Gutenberg-Universität MainzMainzGermany
  2. 2.Department of Medicine-DIMEDUniversity of PadovaPadovaItaly

Personalised recommendations